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ment rate of 90%) and B (drugs at reimbursement rate of 50%) were observed.
RESULTS: In 2010, total expenditure for all prescription drugs was €36.5 million. In
2011, total expenditure for all prescription drugs was €43.2 million. Thus, there was
a cost / consumption increase of 18.23% across the board. Cardiovascular thera-
peutic area carried most of the burden in 2010 and 2011 with the above average
increase of 26.46% amounting to 31.44% of total consumption in 2011
CONCLUSIONS: Moderate increase in cost / consumption from 2010 to 2011 pre-
dominantly accounts for disease management medicines.
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OBJECTIVES:To define the factors which affect the price of single pill combinations
of antihypertensive including angiotensin receptor blockers (ARB) in Turkey and to
estimate the price of amlodipine / valsartan 10/320 mg combination (28 package).
METHODS: ARBs in single pill combination (SPC) with calcium channel blocker
(CCB) or diuretics were evaluated. The prices of the only reimbursed combinations
were abstracted from the price list of the Turkish Ministry of Health. ARB type, dose
increment regarding minimum available dose of ARB, CCB and diuretics in the
market, being original drug and package size were analyzed as predictor in a re-
gression model to estimate the price of the combination. RESULTS: In Turkey, 113
SPCs which include candesartan or eprosartan or irbesartan or losartan or olmesar-
tan or telmisartan or valsartan as ARB, and hydrochlorothiazide as diuretic or
amlodipine as CCB are currently reimbursed. The regression model showed that
ARB type, dose increment in ARB and amlodipine and package size can be used to
predict combination price (B0.89, 4.01, 12.61 and 0.87 respectively; P0.0001 for
all). Being original drug or dose increment in HCTZ have no significant effect on
price (B-0.028, P0.312; B0.001, P989, respectively). The model explains 92% of
variance in drug price. The price of the amlodipine / valsartan 10/320 mg (28 pack-
age) is estimated to be 55.91 TL (24.59 Euro) (95% CI 52.46 – 59.12 TL) by using the
formula. CONCLUSIONS: The formula can be used for estimating the price of the
new SPC, when ARB type, ARB and amlodipine – if used in combination-, package
size are known. Interestingly neither adding HCTZ nor being original drug affect
price of the antihypertensive SPCs in Turkey.
PCV121
RELATIONSHIP BETWEEN PRIMARY CARE PHYSICIANS PROFILE, SELF-
PERCEIVED HEALTH AND RECOMMENDATIONS TO THEIR PATIENTS
Font B1, Lahoz R1, Roldan C1, Banegas JR2, Llisterri JL3, Lobos JM4, Gamarra J5, del Campo
A6, Ruilope LM7
1Novartis Farmaceutica, Barcelona, Spain, 2Universidad Autónoma de Madrid/CIBERESP/IdiPaz,
Madrid, Spain, 3C.S. Ingeniero Joaquín Benlloch, Valencia, Spain, 4C.S. Villablanca, Madrid,
Spain, 5C.S. Medina del Campo Rural, Medina del Campo, Spain, 6Sociología y Comunicación,
Madrid, Spain, 7Hospital Universitario 12 de Octubre, Madrid, Spain
OBJECTIVES: To describe primary care (PC) physicians’ attitudes towards their
health and work in order to segment them in typological groups, and to establish
the relationship between self-perceived cardiovascular (CV) health of physicians
with the recommendations to their patients. METHODS: Cross-sectional study,
through a survey, on PC physicians in Spain. Data on socio-demographic, self-
perceived CV risk and self-assessed consistency between recommendations and
personal practice were collected. The attitude of physicians was estimated based
on the degree of agreement to a set of given phrases. A cluster analysis was per-
formed to identify population segments. RESULTS:A total of 2,583 physicians were
recruited (53.4% women, meanSD age 44.99.3 years), 77.6% of them had 10
years of professional experience. 76.6% perceived their current CV risk as low,
19.9% moderate and 3.5% high. The different physicians’ attitudes clustered them
into two general groups and five subgroups: 40% of physicians were classified as
proactive and close to their patients (24% of them were seeing by the patients as an
example, and 16% were strongly motivated and responsible), and 60% were
grouped as distant and sceptical (20% reserved and distant, without influence of
professional experience in self-care, 20% self-critical, sceptical that their knowl-
edge and health may influence their patients, and 20% unmotivated and critical
with the system). 76.6% of physicians considered to be fairly or completely consis-
tent between what they did and what they recommended to their patients. Twen-
ty-four percent of physicians with more years of experience were completely con-
sistent vs. 18.7% with less experience (p0.01). By gender, 24.3% of men were
completely consistent vs. 21.6% of women (p0.05). CONCLUSIONS: Only four out
of ten physicians were close to their patients and eight considered having a low CV
risk and declared to be consistent between what they do and what they recom-
mend to their patients.
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OBJECTIVES: Hypertension is an established risk factor of cardiovascular disease.
However, its impact on disability-free life expectancy (DFLE) is not well known,
especially in Japan, which has the top-ranked life expectancy worldwide.
METHODS: NIPPON DATA80 and NIPPON DATA90 were two nationwide cohort
studies conducted in Japan, in which participants came from random-sample sur-
veys in the years 1980 and 1990. The DFLE of each hypertension group at the age of
60 years was calculated using the Sullivan method. This estimation was based on
age-specific mortality rates of each hypertension group, estimated by Poisson re-
gression using NIPPON DATA80, and the disability prevalence of each hypertension
group, estimated by logistic regression using NIPPON DATA90. To consider the
effect of smoking on DFLE, we set conditions on the smoking status in the regres-
sion model. The blood pressure at baseline was used to categorize hypertension
(mmHg, systolic blood pressure/diastolic blood pressure): optimal (120/80), pre-
hypertension (120–139/80–89), hypertension I (140–159/90–99), and hypertension
II (160/100). The disability prevalence was measured by the Katz activity of daily
living scale. RESULTS: Among men/women who never smoked, DFLE (years) at age
60 was 21.1/21.9 for optimal hypertension, 20.9/21.6 for prehypertension, 19.8/20.8
for hypertension I, and 18.9/20.1 for hypertension II. This consistent decrease in
hypertension grade was also observed in men and women who were currently
smoking: DFLE (years) at age 60 was 19.0/21.0 (optimal), 18.7/20.7 (prehyperten-
sion), 17.6/19.9 (hypertension I), and 16.6/19.1 (hypertension II). CONCLUSIONS: In
Japan, DFLE decreases as hypertension grade increases. A strategy for reducing
hypertension is recommended to expand the DFLE in Japan.
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OBJECTIVES: To evaluate venous thromboembolism (VTE) prophylaxis pattern for
total knee arthroplasty (TKA) and total hip arthroplasty (THA) in the context of
Brazilian health care system.METHODS: Retrospective medical chart review study
of patients undergoing elective TKA or THA in 2010. All charts were from either one
public or two private hospitals in São Paulo, Brazil. Patients were 18 years old, and
excluded from the study if antithrombotic drugs were used prior to surgery. De-
scriptive analysis was performed through frequency distributions and mean/stan-
dard deviation (SD). RESULTS: From a total of 233 patients, 215 (92.3%) were in-
cluded in the study: 121 (56.3%) TKA and 94 (43.7%) THA. Mean age was 68.2 (SD 9.8)
years and 75.2% were female in the TKA group while, in the THA group mean age
was 56.3 yrs (SD 15.6) and 53.2% were female.. From the public hospital, 71/81
(87.7%) patients received drug prophylaxis, being enoxaparin the choice of treat-
ment. Enoxaparin onset mean time was 29hs after both surgery types. Mean inpa-
tient treatment duration was 3 (TKA) and 4 days (THA). In private hospitals 132/134
(98.5%) received prophylaxis. Treatment of choice was enoxaparin in 130 (98.5%),
while dabigatran and compression stocking in one case each. Compression stock-
ing represented adjuvant prophylaxis in 16.7%. Onset mean time was 20hs after
TKA and 17hs after THA for enoxaparin while 46hs for dabigatran. Mean inpatient
treatment duration was 4 days(enoxaparin) and 3 days (dabigatran).
CONCLUSIONS: The intra-hospitalar prevention rates of VTE in this study is within
international (ENDORSE 2008), practice, while with lower rates in the public. There
are uncertainties that outpatients received the same level of VTE prophylaxis. It is
important to continue the awareness of the clinical and economic impact of VTE
after orthopedic surgery, mainly in the outpatient care.
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Tuberculosis (TB) is one of the most common infectious diseases caused by Myco-
bacterium tuberculosis. The wide prevalence of tuberculosis all over the world
makes it social and economical burden especially for developing countries and the
use of anti tuberculous drugs is an optimistic approach for this problem.Certain
adverse reaction associated with antituberculosis use need to be properly evalu-
ated especially antituberculosis treatment induced liver injury and the
hepatotoxicity. OBJECTIVES: Assessment of the severity and frequency of liver
injury and hepatotoxicity caused by different anti-tuberculosis treatment drugs.
METHODS: Seventy five patients randomly selected from newly diagnosed TB pa-
tients referred to Abo-Seta hospital in Tripoli, Libya for treatment during period
from 1 January to 30 June. All patients received Directly Observation Treatment for
Short period (DOTS) antituberculosis regime. Blood samples for liver function tests
were obtain before starting the treatment and monthly assessment after starting
the treatment for 6 months. RESULTS: In our study the patients developed ATT
induced hepatotoxicities by increasing of all three enzymes 43.9% For alanine
amino transferase (ALT), 36.6% for AST and 44.6% for ALK. Serious liver dysfunction
in the first month compare with control sample, 36.25  1.39 U/L, after one month
increased to 64.6  3.55 U/L, n 75, (P  0.05) from the sample before treatment.
Alkaline phosphatase (ALP) shows increase after one month of treatment from
156.17  21.35 U/L, after one month 281.83  45.8 U/L, n 75, (P  .05).
CONCLUSIONS: There is significant increase in liver enzymes after starting of
DOTS regime.
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